Rosiglitazone not linked with increased mortality

SAN FRANCISCO (Reuters Health) - A nearly 7-year study of the effect of intensive blood sugar control with rosiglitazone (Avandia, GlaxoSmithKline) on the progression of cardiovascular disease in type 2 diabetes showed a slight reduction in cardiovascular events, but unlike the results of a similar study reported earlier this year, the dr...

Continue to Rosiglitazone not linked with increased mortality on Reuters Health eLine.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz